Laurus Labs Limited (LAURUSLABS) Q1 Results FY27 Preview: Date, Time, Expectations & Key Things To Watch

CompoundingAI Research Updated July 19, 2026 3 min read

Laurus Labs enters its Q1 FY27 results with strong momentum in its CDMO segment and a significant tailwind from the 12–14% year-on-year depreciation of the rupee. Investors will be closely watching whether this export-led growth and improved operating leverage can sustain the margin expansion seen in recent quarters.

Quick Details

Results date	July 24, 2026
Quarter	Q1 FY 2026-2027
Previous quarter revenue	Rs. 1,812 Cr
Previous quarter PAT	Rs. 282 Cr
Previous quarter EBITDA margin	28.27%
Market cap	Rs. 82,647.38 Cr
CMP	Rs. 1,529.8

Laurus Labs Limited Q1 Results Date and Time

The board meeting is scheduled for July 24, 2026, to consider the audited financial results and recommend dividend for FY 2026-2027.

What to expect from Laurus Labs Limited's Q1 FY27 results

Revenue growth is anticipated to be supported by the 12–14% year-on-year depreciation of the rupee, which moved from a range of Rs. 83–84 in Q1 FY26 to Rs. 94.50–97.00 in Q1 FY27. EBITDA margins are likely to show expansion over the Q1 FY26 base of 24.85%, potentially remaining near the Q4 FY26 level of 28.27% due to sustained operating leverage and a favorable CDMO product mix. While the antiretroviral (ARV) API segment continues to face revenue erosion, its diluting share in the total revenue mix is expected to moderate the impact on overall growth. Working capital remains a key monitorable, particularly following the Rs. 141 Cr inventory build observed in Q4 FY26, which saw total inventories reach Rs. 2,342 Cr.

Key Things To Watch

CDMO and Segment Performance: Monitoring the shift in revenue composition as the company scales its contract manufacturing business.

Assess if CDMO segment share has reached an inflection point in total revenue and profit contribution
Updates on large contract wins or project pipeline developments
Trajectory of the ARV segment to determine if the decline is bottoming out

Operational and Financial Metrics: Tracking the impact of currency fluctuations and working capital management on bottom-line results.

Quantification of FX tailwinds versus raw material cost inflation in the gross margin bridge
Status of the inventory build from Q4 FY26 (Rs. 2,342 Cr) and its impact on cash conversion
Capex updates for FY27 following the Rs. 1,070 Cr expenditure in FY26

Strategic and Regulatory Updates: Key developments regarding corporate structure and regulatory standing.

NCLT status update on the Laurus Synthesis demerger, which has an appointed date of April 1, 2026
Operational implications of the zero-observation USFDA EIR report received for the Unit 2 facility in June 2026

Frequently Asked Questions

How did the rupee's depreciation impact Laurus Labs' financials?

The 12–14% year-on-year depreciation of the rupee against the USD acts as a significant tailwind for the company, as over 70% of its revenue is USD-denominated. This currency movement provides a mechanical boost to reported revenue and gross margins for the export-led CDMO and API business.

What is the status of the Laurus Synthesis demerger?

The composite scheme for the demerger of Laurus Synthesis has an appointed date of April 1, 2026. Investors are looking for updates regarding progress with the NCLT during the upcoming results call.

Is the company's inventory level a concern for investors?

Consolidated inventories rose to Rs. 2,342 Cr as of March 31, 2026, compared to Rs. 1,936 Cr a year earlier. Analysts are monitoring whether this inventory build continued into Q1 FY27 or if it has begun to unwind to support cash flow.